<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="120">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01215981</url>
  </required_header>
  <id_info>
    <org_study_id>2010NTLS050</org_study_id>
    <secondary_id>MT2010-08R</secondary_id>
    <secondary_id>1007M86296</secondary_id>
    <nct_id>NCT01215981</nct_id>
  </id_info>
  <brief_title>Influenza Vaccine Post Allogeneic Transplant</brief_title>
  <official_title>MT2010-08R Influenza Vaccine Specific Immune Responses After Allogeneic Hematopoietic Cell Transplantation: Are One or Two Vaccine Doses Needed?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Design:

      This is a randomized, single center study to evaluate immune responses to the seasonal
      influenza vaccine in allogeneic hematopoietic stem cell transplant (HSCT) recipients who
      receive one vaccine or two vaccine doses one month apart. In addition, a cohort of healthy
      adult volunteers will be recruited as controls to confirm immune response to a single
      influenza vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Prevention</study_design>
  <primary_outcome>
    <measure>Immune Response to Vaccine</measure>
    <time_frame>8 Weeks After Vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary endpoint of this study is to measure the response to the vaccine with laboratory studies including viral specific B and T cell immune responses (baseline compared to Week 8).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hematopoietic Stem Cell Transplant</condition>
  <condition>Hematologic Malignancy</condition>
  <arm_group>
    <arm_group_label>Participants Receiving 1 Dose of Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group participants (healthy volunteers):
Age 18 to 50 years
No history of previous allergic reaction to influenza vaccine, known egg allergy or Guillan-Barre Syndrome
No flu vaccine in previous 4 months
and/or HSCT recipients who are greater than 60 days post transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants Receiving 2 Doses of Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hematopoietic stem cell transplant (HSCT) recipients who are greater than 60 days post transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccine</intervention_name>
    <description>One dose of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B</description>
    <arm_group_label>Participants Receiving 1 Dose of Vaccine</arm_group_label>
    <other_name>H1N1</other_name>
    <other_name>H3N2</other_name>
    <other_name>Influenza A vaccine</other_name>
    <other_name>Influenza B vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccine</intervention_name>
    <description>Two doses of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B</description>
    <arm_group_label>Participants Receiving 2 Doses of Vaccine</arm_group_label>
    <other_name>Influenza A</other_name>
    <other_name>H1N1</other_name>
    <other_name>N3N2</other_name>
    <other_name>Influenza B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient Population

               -  HSCT recipients who are greater than 60 days post transplant.

               -  Age 6 months and older who are greater than 60 days post post allogeneic
                  hematopoietic cell transplant

               -  Show neutrophil recovery, platelet count &gt; 50,000/mm3 (may be transfused), no
                  known disease relapse

               -  No history of previous allergic reaction to influenza vaccine, known egg allergy
                  or Guillan-Barre Syndrome

               -  No flu vaccine in previous 4 months, no Campath in previous 6 months, no
                  intravenous immune globulin (IVIG) in previous 3 months

          -  Controls:

               -  Age 18 to 50 years

               -  No history of previous allergic reaction to influenza vaccine, known egg allergy
                  or Guillan-Barre Syndrome

               -  No flu vaccine in previous 4 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Verneris, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Verneris, M.D.</last_name>
    <phone>612-626-2961</phone>
    <email>verneris@umn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Verneris, M.D.</last_name>
      <phone>612-626-2961</phone>
      <email>verneris@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Verneris, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <lastchanged_date>October 18, 2011</lastchanged_date>
  <firstreceived_date>October 5, 2010</firstreceived_date>
  <responsible_party>
  </responsible_party>
  <keyword>influenza vaccine</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
</clinical_study>
